142 related articles for article (PubMed ID: 15643095)
1. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.
Lambert BL; Chang KY; Tafesse E; Carson W
J Clin Psychopharmacol; 2005 Feb; 25(1):12-8. PubMed ID: 15643095
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
3. Hyperlipidemia following treatment with antipsychotic medications.
Olfson M; Marcus SC; Corey-Lisle P; Tuomari AV; Hines P; L'Italien GJ
Am J Psychiatry; 2006 Oct; 163(10):1821-5. PubMed ID: 17012695
[TBL] [Abstract][Full Text] [Related]
4. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
Koro CE; Fedder DO; L'Italien GJ; Weiss S; Magder LS; Kreyenbuhl J; Revicki D; Buchanan RW
Arch Gen Psychiatry; 2002 Nov; 59(11):1021-6. PubMed ID: 12418935
[TBL] [Abstract][Full Text] [Related]
5. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.
Lund BC; Perry PJ; Brooks JM; Arndt S
Arch Gen Psychiatry; 2001 Dec; 58(12):1172-6. PubMed ID: 11735847
[TBL] [Abstract][Full Text] [Related]
6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
7. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
[TBL] [Abstract][Full Text] [Related]
9. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine.
Ramaswamy K; Kozma CM; Nasrallah H
Drug Saf; 2007; 30(7):589-99. PubMed ID: 17604410
[TBL] [Abstract][Full Text] [Related]
10. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design.
Gianfrancesco F; Pesa J; Wang RH; Nasrallah H
Am J Health Syst Pharm; 2006 Mar; 63(5):431-41. PubMed ID: 16484517
[TBL] [Abstract][Full Text] [Related]
11. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
12. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Citrome L; Jaffe A; Levine J; Allingham B; Robinson J
Psychiatr Serv; 2004 Sep; 55(9):1006-13. PubMed ID: 15345760
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis.
Bloechliger M; Rüegg S; Jick SS; Meier CR; Bodmer M
CNS Drugs; 2015 Jul; 29(7):591-603. PubMed ID: 26242478
[TBL] [Abstract][Full Text] [Related]
15. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
16. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
17. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
J Clin Psychiatry; 2006 Jul; 67(7):1055-61. PubMed ID: 16889448
[TBL] [Abstract][Full Text] [Related]
18. New generation antipsychotics for first episode schizophrenia.
Rummel C; Hamann J; Kissling W; Leucht S
Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012
[TBL] [Abstract][Full Text] [Related]
19. Exposure to potentially dangerous drug-drug interactions involving antipsychotics.
Guo JJ; Wu J; Kelton CM; Jing Y; Fan H; Keck PE; Patel NC
Psychiatr Serv; 2012 Nov; 63(11):1080-8. PubMed ID: 22910806
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia.
Stroup TS; Gerhard T; Crystal S; Huang C; Olfson M
Am J Psychiatry; 2016 Feb; 173(2):166-73. PubMed ID: 26541815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
